Navigation Links
Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Date:9/7/2007

most commonly diagnosed cancer in men, accounting for 30 percent of all male cancers, and prostate cancer is second only to lung cancer as a leading cause of male cancer deaths. Currently, there is no cure for locally advanced or metastatic prostate cancer.

"We are delighted that bavituximab shrank resistant human prostate tumors in this study, an important new sign of its potential anti-cancer efficacy," said Steven W. King, president and CEO of Peregrine. "Preclinically, we have now shown that adding bavituximab equivalent antibodies to combination regimens significantly enhances the anti-tumor activity of cancer chemotherapy, of hormone deprivation therapy and of radiation therapy in prostate, breast, lung, brain and pancreatic cancers. The breadth of these potential applications supports many options for future clinical studies."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial in advanced cancer patients to assess its safety in combination with common chemotherapy agents, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

This study, entitled "Vascular Targeting Antib
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. NIEHS Researchers Identify Enzyme Critical in DNA Replication
8. Stanford Researchers Find Brain Pathway of Depression in Rats
9. Researchers Discover Method for Identifying How Cancer Evades the Immune System
10. Researchers Discover Gene For Rare Skin Disorder
11. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... 2011 ChromaDex® Corp. (OTCBB: CDXC) today announced ... ChromaDex® the exclusive rights to a joint patent ... the method of inducing UDP-glucuronosyltransferase (UGT) activity using ... found in blueberries and demonstrated to have multiple ...
... (Nasdaq: NKTR ) today announced that dosing ... multiple ascending doses of NKTR-181, the company,s novel opioid ... once- or twice-daily oral tablet for the treatment of ... liability and serious central nervous system (CNS) side effects ...
Cached Medicine Technology:ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 2ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6
(Date:8/30/2014)... a plant-based medication commonly used to treat gout, ... in reducing potential complications from this type of ... gastrointestinal adverse effects, according to a study published ... released early online to coincide with its presentation ... Common complications after cardiac surgery include postpericardiotomy syndrome ...
(Date:8/30/2014)... "My niece developed a nighttime fever, ... moment, her fever might get worse," said an inventor ... aware of how she was doing, I developed this ... continuously monitor a child's temperature. The unit instantly alerts ... that prompt medical care can be given, which is ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Bringing forth ... By Search announces the Labor Day discount on ... will surely get the complete services related to internet ... professionals, Content Writers, and others do have a deep ... that reflects in their work and since the inception, ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "I had ... because of her crutches," said an inventor from Wetumpka, Ala. ... sights and sounds of the shore, I came up with ... sand." , She created a prototype for the patent-pending Deezers ... accessory enables the individual to use crutches, walkers, or canes ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... ... WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ESMC ... 2008., For the first quarter of fiscal 2009, the Company ... This,included product revenue of $8,669,000 for the first quarter of fiscal,2009, ...
... Nov. 13 The fourth annual EagleBank,Foundation Fight ... local hospitals were the primary beneficiaries: Shady Grove,Adventist ... and The,George Washington University Hospital, Providence Hospital and ... the Primary Care,Coalition of Montgomery County. The tournament ...
... FORT LAUDERDALE, Fla., Nov. 13 eDiets.com,Inc. (Nasdaq: ... fitness,and healthy lifestyle solutions, today announced results for the ... Revenues for the third quarter of 2008 were $4.8 ... Net loss for the quarter was $(3.2),million, or $(0.13) ...
... urging safe sex practices, study says , , THURSDAY, ... for pelvic inflammatory disease (PID) become highly vulnerable ... or months after treatment, researchers at Johns Hopkins ... the researchers, suggest that treating PID "with a ...
... Nov. 13 Watson,Pharmaceuticals, Inc. (NYSE: ... announced that its New Drug Application (NDA) ... a luteinizing hormone,releasing hormone (LHRH) agonist, has ... and Drug Administration (FDA). Watson is seeking ...
... 13 In a regular session of,the New York ... the cover of,a contentious election year and an economic ... Appeals (NYCOA) declined to hear the appeal of,Kathryn Jordan ... by a woman with Multiple Sclerosis. The appeal was,filed ...
Cached Medicine News:Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000 2Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5